Please ensure Javascript is enabled for purposes of website accessibility

Why Immutep Limited Stock Popped Today

By Prosper Junior Bakiny - Apr 8, 2021 at 5:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the company's latest regulatory update.

What happened

Shares of Australia-based biotech Immutep Limited (IMMP -1.88%) rose sharply on Thursday thanks to the company's announcement of a regulatory update regarding one of its pipeline candidates, investigational cancer treatment eftilagimod alpha. Immutep Limited's stock ended the day up by 11.3% after jumping by as much as 14.8% during the trading session. 

So what

Immutep Limited reported that the U.S. Food and Drug Administration (FDA) granted the Fast Track designation to eftilagimod alpha in the treatment of recurring or metastatic head and neck squamous cell carcinoma (HNSCC). What does this mean? The Fast Track designation is given to drugs that fill an unmet medical need to expedite their development and approval. It ensures that the company in question and the FDA will work closely together at every step of the process.

Man on a ladder drawing an upward-bound graph on a board.

Image source: Getty Images.

One more perk of Fast-Tracked investigational drugs: The FDA allows rolling submissions from these experimental medicines. Rolling submissions of investigational drugs allow companies to submit completed sections of a New Drug Application (NDA) instead of submitting the entire application all at once, thereby speeding up the process. The FDA decided to grant eftilagimod alpha the Fast Track designation after the company released data from a phase 2 clinical trial of the medicine in combination with Keytruda (a cancer drug marketed by Merck) in the treatment of patients with HNSCC.

Now what

Shares of small-cap biotechs like Immutep Limited often rise as a result of positive regulatory updates. However, investors should focus on the long-term prospects of the healthcare company. As things stand, Immutep Limited looks like a risky bet given that it has no products on the market and most of its pipeline candidates are still in their early stages of development. The company does have quite a few big-name partners in the pharmaceutical field, including Merck, Pfizer, and others. This may indicate that Immutep Limited's investigational treatments are promising. Even so, I'd caution against purchasing shares of this biotech stock, at least for now. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immutep Limited Stock Quote
Immutep Limited
$2.61 (-1.88%) $0.05
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.10 (-0.97%) $0.90
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.40 (-1.83%) $0.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.